MENÚ
Publicaciones
TELÉFONOS HOSPITAL LUCUS AUGUSTI
Información
982 295475
982 295475
Att. Paciente
982 297029
982 297029
Admisión
982 266480
982 266480
Cita Previa
982 296008
982 296008
09 de Diciembre de 2021
Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
J Investig Allergol Clin Immunol 2020;30(5):307-316. doi: 10.18176/jiaci.0628. Epub 2020 Jun 23. PMID: 32573459.
09 de Diciembre de 2021
Treatment of Moderate- severe Asthma: An Alternative Strategy to the Guidelines Recommendations.
Arch Bronconeumol (Engl Ed) 2021 Apr;57(4):243-245. English, Spanish. doi: 10.1016/j.arbres.2020.04.017. Epub 2020 Jun 1. PMID: 32499097.
09 de Diciembre de 2021
EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy.
2021 Jan;76(1):14-44. doi: 10.1111/all.14425. Epub 2020 Aug 10. PMID: 32484954.
09 de Diciembre de 2021
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy.
2020 May;75(5):1058-1068. doi: 10.1111/all.14268. Epub 2020 Apr 1. PMID: 32154939.
09 de Diciembre de 2021
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy.
2020 May;75(5):1043-1057. doi: 10.1111/all.14235. PMID: 32064642.
09 de Diciembre de 2021
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy.
2020 May;75(5):1023-1042. doi:10.1111/all.14221. Epub 2020 Feb 24. PMID: 32034960
